Shanghai Trial Hid 6-Year-Old's Death After $860,000 Gene Therapy Push
Updated
Updated · Retraction Watch · Jul 24
Shanghai Trial Hid 6-Year-Old's Death After $860,000 Gene Therapy Push
3 articles · Updated · Retraction Watch · Jul 24
Summary
Seven days after doctors infused trillions of virus particles carrying a base editor into her spinal fluid, a 6-year-old girl died from a severe immune reaction in a one-patient Shanghai trial.
$860,000 from the family helped fund the treatment's development, but that payment and the fatal outcome were not publicly disclosed in trial records or a Nature paper describing related preclinical work.
Seven outside experts told Science and Retraction Watch the team may have downplayed risks, missed animal-study safety signals and advanced a therapy with little chance of success; some said the paper could warrant retraction.
Xinhua Hospital reportedly used a regulatory pathway that did not require national approval, sharpening concerns about weak oversight and secrecy in China's fast-growing gene-editing research.
Why did a prestigious medical journal publish a fatal gene-editing trial while crucial animal safety data and an $860,000 payment remained hidden?
What happens when desperate parents pay nearly a million dollars for an experimental cure, only to face hidden risks and zero accountability?
Can the June 2026 regulatory overhaul truly prevent another tragedy, or is the global biotech race still prioritizing speed over human lives?
The 2025 Shanghai Gene-Editing Tragedy: Mei’s Death, $860,000 Family Funding, and the Global Backlash Against Unregulated Trials
Overview
In March 2025, Mei, a young girl with a rare CHD3 gene mutation, became the subject of a high-risk, family-funded gene-editing trial in Shanghai. Her parents invested their savings, trusting a leading neuroscientist, but the hospital approved the experiment without reviewing alarming primate safety data. Mei received a massive dose of engineered viruses, leading to a fatal immune reaction within days. The research team ignored preclinical warnings and later covered up her death, publishing misleading results. When the truth emerged, global outrage followed, prompting China to tighten regulations and ban patient-funded experimental trials to prevent future tragedies.